BioPorto (CO:BIOPOR) — Market Cap & Net Worth
Market Cap & Net Worth: BioPorto (BIOPOR)
BioPorto (CO:BIOPOR) has a market capitalization of $89.86 Million (Dkr574.31 Million) as of June 17, 2026. Listed on the CO stock exchange, this Denmark-based company holds position #19702 globally and #83 in its home market, demonstrating a -7.57% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying BioPorto's stock price Dkr1.16 by its total outstanding shares 495095887 (495.10 Million). Review BioPorto total liabilities to assess the company's total debt and financial obligations.
BioPorto Market Cap History: 2015 to 2026
BioPorto's market capitalization history from 2015 to 2026. Data shows change from $373.36 Million to $89.86 Million (-7.62% CAGR).
BioPorto Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how BioPorto's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.96x
BioPorto's market cap is 1.96 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $162.67 Million | $20.72 Million | -$22.80 Million | 7.85x | N/A |
| 2017 | $256.40 Million | $25.16 Million | -$32.24 Million | 10.19x | N/A |
| 2018 | $271.11 Million | $26.02 Million | -$38.05 Million | 10.42x | N/A |
| 2019 | $226.96 Million | $26.62 Million | -$69.64 Million | 8.53x | N/A |
| 2020 | $312.94 Million | $23.20 Million | -$61.56 Million | 13.49x | N/A |
| 2021 | $191.33 Million | $24.25 Million | -$57.11 Million | 7.89x | N/A |
| 2022 | $179.32 Million | $28.97 Million | -$75.92 Million | 6.19x | N/A |
| 2023 | $161.89 Million | $30.96 Million | -$56.33 Million | 5.23x | N/A |
| 2024 | $120.07 Million | $36.24 Million | -$68.24 Million | 3.31x | N/A |
| 2025 | $79.01 Million | $40.29 Million | -$82.12 Million | 1.96x | N/A |
Competitor Companies of BIOPOR by Market Capitalization
Companies near BioPorto in the global market cap rankings as of June 17, 2026.
Key companies related to BioPorto by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #127 globally with a market cap of $177.57 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #182 globally with a market cap of $128.10 Billion USD.
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #626 globally with a market cap of $44.18 Billion USD.
- LONZA GROUP UNSP.ADR 1/10 (F:LO3A): Ranked #663 globally with a market cap of $41.04 Billion USD ( €35.10 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #127 | Thermo Fisher Scientific Inc | NYSE:TMO | $177.57 Billion | $472.63 |
| #182 | Danaher Corporation | NYSE:DHR | $128.10 Billion | $181.35 |
| #626 | IDEXX Laboratories Inc | NASDAQ:IDXX | $44.18 Billion | $573.00 |
| #663 | LONZA GROUP UNSP.ADR 1/10 | F:LO3A | $41.04 Billion | €54.50 |
BioPorto Historical Marketcap From 2015 to 2026
Between 2015 and today, BioPorto's market cap moved from $373.36 Million to $ 89.86 Million, with a yearly change of -7.62%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Dkr89.86 Million | +13.73% |
| 2025 | Dkr79.01 Million | -34.19% |
| 2024 | Dkr120.07 Million | -25.84% |
| 2023 | Dkr161.89 Million | -9.72% |
| 2022 | Dkr179.32 Million | -6.28% |
| 2021 | Dkr191.33 Million | -38.86% |
| 2020 | Dkr312.94 Million | +37.88% |
| 2019 | Dkr226.96 Million | -16.29% |
| 2018 | Dkr271.11 Million | +5.74% |
| 2017 | Dkr256.40 Million | +57.62% |
| 2016 | Dkr162.67 Million | -56.43% |
| 2015 | Dkr373.36 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of BioPorto was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $89.86 Million USD |
| MoneyControl | $89.86 Million USD |
| MarketWatch | $89.86 Million USD |
| marketcap.company | $89.86 Million USD |
| Reuters | $89.86 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About BioPorto
BioPorto A/S, an in-vitro diagnostics company, focuses on developing biomarker tests to help clinicians detect the kidney injury in critically ill patients at earlier stage in Denmark, rest of Europe, North America, and Asia. It offers ProNephro AKI (NGAL), a test for pediatric acute kidney injury (AKI); NGAL Test, a particle-enhanced turbidimetric immunoassay for the quantitative determination o… Read more